Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

M Cavo; L Pantani; A Pezzi; MT Petrucci; F Patriarca; F Di Raimondo; G Marzocchi; M Galli; V Montefusco; E Zamagni; B Gamberi; P Tacchetti; A Brioli; AA Palumbo; Pieter Sonneveld

doi:10.1038/leu.2015.274

Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

M Cavo
, L Pantani
, A Pezzi
, MT Petrucci
, F Patriarca
, F Di Raimondo
, G Marzocchi
, M Galli
, V Montefusco
, E Zamagni
, B Gamberi
, P Tacchetti
, A Brioli
, AA Palumbo
, Pieter Sonneveld

Research output: Contribution to journal › Article › Academic › peer-review

55 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	2429-2431
Number of pages	3
Journal	Leukemia
Volume	29
Issue number	12
DOIs	https://doi.org/10.1038/leu.2015.274
Publication status	Published - 2015

Research programs

EMC MM-02-41-03

Access to Document

10.1038/leu.2015.274

Cite this

Cavo, M., Pantani, L., Pezzi, A., Petrucci, MT., Patriarca, F., Di Raimondo, F., Marzocchi, G., Galli, M., Montefusco, V., Zamagni, E., Gamberi, B., Tacchetti, P., Brioli, A., Palumbo, AA., & Sonneveld, P. (2015). Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Leukemia, 29(12), 2429-2431. https://doi.org/10.1038/leu.2015.274

@article{ccca9754495244669dff386525f64b73,

title = "Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma",

author = "M Cavo and L Pantani and A Pezzi and MT Petrucci and F Patriarca and \{Di Raimondo\}, F and G Marzocchi and M Galli and V Montefusco and E Zamagni and B Gamberi and P Tacchetti and A Brioli and AA Palumbo and Pieter Sonneveld",

year = "2015",

doi = "10.1038/leu.2015.274",

language = "Undefined/Unknown",

volume = "29",

pages = "2429--2431",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "12",

}

Cavo, M, Pantani, L, Pezzi, A, Petrucci, MT, Patriarca, F, Di Raimondo, F, Marzocchi, G, Galli, M, Montefusco, V, Zamagni, E, Gamberi, B, Tacchetti, P, Brioli, A, Palumbo, AA & Sonneveld, P 2015, 'Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma', Leukemia, vol. 29, no. 12, pp. 2429-2431. https://doi.org/10.1038/leu.2015.274

TY - JOUR

T1 - Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

AU - Cavo, M

AU - Pantani, L

AU - Pezzi, A

AU - Petrucci, MT

AU - Patriarca, F

AU - Di Raimondo, F

AU - Marzocchi, G

AU - Galli, M

AU - Montefusco, V

AU - Zamagni, E

AU - Gamberi, B

AU - Tacchetti, P

AU - Brioli, A

AU - Palumbo, AA

AU - Sonneveld, Pieter

PY - 2015

Y1 - 2015

U2 - 10.1038/leu.2015.274

DO - 10.1038/leu.2015.274

M3 - Article

C2 - 26442610

SN - 0887-6924

VL - 29

SP - 2429

EP - 2431

JO - Leukemia

JF - Leukemia

IS - 12

ER -